Abstract
Background: Diabetic nephropathy (DN) is currently the most common cause of end-stage renal disease (ESRD). Although nowadays much is known about its classification, pathogenesis, clinical manifestations and evolution, to date we are not yet able to stop the natural progression of nephropathy in diabetic patients.
Methods: Treatment options are: lifestyle change with close blood pressure monitoring and tight glycemic control. The most common therapies adopted for this condition are Angiotensing Converting Enzyme-inhibitors (ACEi). However these drugs are able to block the progression of renal damage only in a small proportion of patients. In the remaining, DN progresses and may evolve into ESRD.
Conclusion: The purpose of this review is to summarize the “state of art” of current novel therapeutic strategies to stem this debilitating kidney disease.
Keywords: Chronic kidney disease, diabetes mellitus, diabetic nephropathy, end stage renal disease, novel therapies.
Current Drug Metabolism
Title:Diabetic Nephropathy: Focus on Current and Future Therapeutic Strategies
Volume: 17 Issue: 5
Author(s): Riccardo Pofi, Francesca Di Mario, Antonietta Gigante, Edoardo Rosato, Andrea M. Isidori, Antonio Amoroso, Rosario Cianci and Biagio Barbano
Affiliation:
Keywords: Chronic kidney disease, diabetes mellitus, diabetic nephropathy, end stage renal disease, novel therapies.
Abstract: Background: Diabetic nephropathy (DN) is currently the most common cause of end-stage renal disease (ESRD). Although nowadays much is known about its classification, pathogenesis, clinical manifestations and evolution, to date we are not yet able to stop the natural progression of nephropathy in diabetic patients.
Methods: Treatment options are: lifestyle change with close blood pressure monitoring and tight glycemic control. The most common therapies adopted for this condition are Angiotensing Converting Enzyme-inhibitors (ACEi). However these drugs are able to block the progression of renal damage only in a small proportion of patients. In the remaining, DN progresses and may evolve into ESRD.
Conclusion: The purpose of this review is to summarize the “state of art” of current novel therapeutic strategies to stem this debilitating kidney disease.
Export Options
About this article
Cite this article as:
Pofi Riccardo, Di Mario Francesca, Gigante Antonietta, Rosato Edoardo, Isidori M. Andrea, Amoroso Antonio, Cianci Rosario and Barbano Biagio, Diabetic Nephropathy: Focus on Current and Future Therapeutic Strategies, Current Drug Metabolism 2016; 17 (5) . https://dx.doi.org/10.2174/138920021705160324165553
DOI https://dx.doi.org/10.2174/138920021705160324165553 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Tissue Distribution and Metabolism of Micro- and Nanoparticles and Medical Implants
With the continuous advancement of modern science and engineering, numerous functional materials and active molecules have been developed and utilized in various industrial, medical, and food applications. Many of these can enter the body, either actively or passively, and have significant and intricate impacts on human health. For example, biomaterials ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Pathophysiology of Contrast-Induced Acute Kidney Injury (CIAKI)
Current Pharmaceutical Design Cell-Penetrating Peptides as a Potential Drug Delivery System for Effective Treatment of Diabetes
Current Pharmaceutical Design A Novel Combined Pharmacophore Mapping and Quantitative Structure Selectivity Relationship Analysis for the Development of Potent and Selective Human Aldose Reductase Inhibitors
Current Computer-Aided Drug Design A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications
Current Hypertension Reviews Hypertension and Cardiovascular Risk: The Importance of a Global Approach to Risk Management in the Light of Current Hypertension Guidelines
Current Hypertension Reviews Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms
Current Genomics Apolipoprotein E Knockout Models
Current Pharmaceutical Design Molecular Mechanisms of Renal Blood Flow Autoregulation
Current Vascular Pharmacology Genes, Environment, Intermediate Phenotypes, and the Pathogenesis of Diabetic Nephropathy
Current Pharmacogenomics Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy Peroxynitrite-Driven Mechanisms in Diabetes and Insulin Resistance – the Latest Advances
Current Medicinal Chemistry Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine
Current Pharmacogenomics and Personalized Medicine Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors
Current Pharmaceutical Design Signal Transduction Therapy of Diabetic Vascular Complication
Current Signal Transduction Therapy Editorial [Hot topic: Vitamin D Deficiency in Cardiovascular and Renal Disease: New Light Shed on an Old Enemy (Guest Editor: Martin H. de Borst)]
Current Drug Targets H19: A Vital Long Noncoding RNA in the Treatment of Diabetes and Diabetic Complications
Current Pharmaceutical Design Antidiabetic Drugs and the Kidney
Current Pharmaceutical Design